more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.16 USD

+0.35 (1.26%)

Updated May 6, 2024 04:00 PM ET

After-Market: $28.26 +0.10 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for PFE

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Oncology: Ibrance: Worl...		4,753	5,120	5,437	5,392	4,961
Revenues: FSME-IMMUN/TicoVac [$M]		268	200	185	196	220
Revenues: Pharmaceutical: Oncolog...		433	357	238	137	470
Revenues: Oncology: Xtandi allian...		1,191	1,198	1,185	1,024	838
Revenues: Oncology: Xtandi allian...		1,191	1,198	1,185	1,024	838
Revenues: Specialty Care: Inflect...		490	532	657	659	625
Revenues: Oncology: Bosulif: Worl...		645	575	540	450	365
Revenue - Oncology: Medrol [$M]		339	328	432	402	469
Pfizer Biopharma: Total [$M]		57,186	98,988	79,557	40,724	--
Revenues: Primary Care: Comirnaty...		11,220	37,806	36,781	--	--
Revenue: Primary Care: Nimenrix: ...		179	268	48	--	--
Revenue: Primary Care: Nurtec ODT...		928	213	0	--	--
Revenue: Specialty Care: Oxbryta:...		328	73	0	--	--
Revenues: Specialty Care: Zavicef...	--	511	412	413	--	--
Revenues: Pharmaceutical: Primary...		1,777	1,932	1,967	--	--
Revenues: Pharmaceutical: Oncolog...		390	458	491	--	--
Revenues: Pharmaceutical: Oncolog...		424	562	444	--	--
Revenues: Pharmaceutical: Oncolog...		213	194	187	--	--
Revenues: Pharmaceutical: Oncolog...		539	343	266	--	--
Revenues: Pharmaceutical: Oncolog...		174	176	155	--	--
Revenues: Pharmaceutical: Oncolog...		236	219	192	--	--
Revenues: Pharmaceutical: Oncolog...		340	394	444	--	--
Revenues: Pharmaceutical: Oncolog...		91	203	197	--	--
Revenues: Pharmaceutical: Special...		584	491	119	--	--
Revenues: Pharmaceutical: Special...		584	491	430	--	--
Revenues: Specialty Care: All oth...		1,092	1,171	1,835	--	--
Revenues: Specialty Care: All oth...		2,244	2,350	2,830	--	--
Revenues: Primary Care: Paxlovid ...		1,279	18,933	76	--	--
Revenue: Specialty Care - Cibinqo...		128	27	--	--	--
Revenue: Business Innovation - Pf...		44	7	--	--	--
Revenues: Specialty Care: BeneFIX...		424	425	438	454	488
Revenue-Pharmaceutical: BMP2 [$M]		338	277	266	274	287
Revenues: Specialty Care: Genotro...		539	360	389	427	498
Revenues: Specialty Care: Fragmin...		238	269	305	252	253
Revenues: Specialty Care: Vfend: ...		187	225	267	270	346
Revenues: Specialty Care: Zithrom...		406	331	278	276	336
Revenue-Pharmaceutical: Oncology-...		301	248	211	148	--
Revenues: Oncology: Sutent: World...		180	347	673	819	936
Revenues: Specialty Care: Refacto...		230	239	304	370	426
Revenues: Specialty Care: Sulpera...		757	786	683	618	684
Revenues: Specialty Care: Somave...		267	268	277	277	264
Revenues: Oncology: Inlyta: World...		1,036	1,003	1,002	787	477
Revenues: Oncology: Xalkori: Worl...		374	465	493	544	530
Revenue: Primary Care: Worldwide ...		30,589	73,023	52,029	--	--
Revenue: Specialty Care: Worldwid...		14,970	13,833	15,194	--	--
Revenues: Oncology: Worldwide [$M...		11,627	12,132	12,333	10,867	9,014
Revenues: Pfizer CentreOne: World...		1,265	1,335	1,731	926	--
Revenues: Primary Care: Eliquis a...		6,747	6,480	5,970	4,949	4,220
Revenues: Primary Care: Prevnar f...		6,440	6,337	5,272	5,850	--
Revenues: Primary Care: Premarin ...		397	455	563	680	734
Revenues: Specialty Care: Vyndaqe...		3,321	2,447	2,015	1,288	473
Revenues: Specialty Care: Xeljanz...		1,703	1,796	2,455	2,437	2,242
Revenues: Specialty Care: Enbrel:...		830	1,003	1,185	1,350	1,699
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Oncology: Ibrance; Unit...		3,151	3,370	3,418	3,634	3,250
Revenues: Oncology: Ibrance: Tota...		1,602	1,751	2,019	1,758	1,710
Revenues: FSME-IMMUN/TicoVac - US...		3	2	0	--	--
Revenue: Pharmaceutical-All Other...		300	216	129	91	219
Revenue: Pharmaceutical-All Other...		133	140	109	46	251
Revenue: FSME/IMMUN-TicoVac: ROW ...		265	198	185	196	--
Revenues: Specialty Care: Inflect...		257	289	385	341	300
Revenues: Specialty Care: Inflect...		233	243	272	318	325
Revenues: Primary Care: Eliquis a...		2,519	2,658	2,810	2,260	1,877
Revenues: Oncology: Bosulif: Unit...		444	375	354	304	243
Revenues: Oncology: Bosulif: Tota...		200	200	186	146	122
Revenue: Pharmaceutical-Oncology ...		7,627	7,921	7,736	7,048	5,591
Revenue: Pharmaceutical-Oncology ...		4,000	4,210	4,597	3,819	3,422
Pfizer Biopharma: US [$M]		26,698	42,083	29,221	21,055	--
Pfizer Biopharma: ROW [$M]		30,488	56,905	50,336	19,670	--
Revenues: Specialty Care: Vyndaqe...		1,863	1,245	909	613	191
Revenues: Specialty Care: Vyndaqe...		1,458	1,202	1,106	675	282
Revenue: Primary Care: Nimenrix: ...		179	268	48	--	--
Revenue: Specialty Care: Oxbryta:...		323	72	0	--	--
Revenue: Specialty Care: Oxbryta:...		5	0	0	--	--
Revenues: Specialty Care: Zavicef...	--	511	412	107	--	--
Revenues: Pharmaceutical: Primary...		315	340	45	--	--
Revenues: Pharmaceutical: Primary...		1,462	1,592	433	--	--
Revenue: Specialty Care - Cibinq...		46	11	--	--	--
Revenue: Specialty Care - Cibinq...		81	16	--	--	--
Revenue: Specialty Care - All oth...		258	317	511	--	--
Revenue: Specialty Care - All oth...		834	854	1,324	--	--
Revenue: Specialty Care - All oth...		1,280	1,351	1,608	--	--
Revenue: Specialty Care - All oth...		965	999	1,223	--	--
Revenue: Pharmaceutical-Specialty...		6,601	5,659	6,156	--	--
Revenue: Pharmaceutical-Specialty...		8,370	8,174	9,038	--	--
Revenue: Pharmaceutical- Oncology...		304	413	246	--	--
Revenue: Pharmaceutical- Oncology...		119	149	197	--	--
Revenue: Pharmaceutical- Oncology...		308	403	450	--	--
Revenue: Pharmaceutical- Oncology...		82	55	41	--	--
Revenue: Pharmaceutical- Oncology...		259	312	344	--	--
Revenue: Pharmaceutical- Oncology...		81	82	100	--	--
Revenue: Pharmaceutical-Oncology-...		224	177	141	--	--
Revenue: Pharmaceutical-Oncology-...		314	166	125	--	--
Revenue: Pharmaceutical-Oncology-...		134	126	115	--	--
Revenue: Pharmaceutical-Oncology-...		102	93	77	--	--
Revenue: Pharmaceutical-Oncology-...		203	191	187	--	--
Revenue: Pharmaceutical-Oncology-...		10	3	--	--	--
Revenue: Pharmaceutical-Oncology-...		-8	106	98	--	--
Revenue: Pharmaceutical-Oncology-...		99	97	99	--	--
Revenue: Pharmaceutical-Oncology-...		171	175	155	--	--
Revenue: Pharmaceutical-Oncology-...		3	1	--	--	--
Geographic Revenue: United States...		27,088	42,473	29,746	21,455	20,326
Geographic Revenue: Total Interna...		31,408	57,857	51,542	20,196	20,579
Revenue: Primary Care: Comirnaty ...		7,582	8,537	7,652	5,418	4,648
Revenues: Specialty Care: BeneFIX...		200	191	207	215	246
Revenues: Specialty Care: BeneFIX...		225	235	230	239	242
Revenue-Pharmaceutical: BMP2-Unit...		338	277	266	274	287
Revenues: Specialty Care: Enbrel:...		830	1,003	1,185	1,350	1,699
Revenues: Specialty Care: Genotro...		386	292	310	299	405
Revenues: Specialty Care: Genotro...		153	68	79	128	93
Revenue-Pharmaceutical: Fragmin-I...		236	264	300	245	244
Revenue-Pharmaceutical: Fragmin-U...		2	4	5	7	9
Revenue-Pharmaceutical: Infectiou...		6	5	8	20	13
Revenue-Pharmaceutical: Infectiou...		181	221	260	250	333
Revenue-Pharmaceutical: Infectiou...		404	328	278	271	338
Revenue-Pharmaceutical-Medrol: In...		206	196	251	204	221
Revenue-Pharmaceutical-Medrol: Un...		132	132	181	198	248
Revenue-Pharmaceutical: Oncology-...	--	298	246	208	--	--
Revenue-Pharmaceutical: Oncology-...		2	2	3	--	--
Revenues: Oncology: Sutent: Total...		160	314	546	597	653
Revenues: Oncology: Sutent: Unite...		20	33	127	223	283
Revenues: Primary Care: Premarin ...		36	36	38	42	44
Revenues: Primary Care: Premarin ...		361	420	525	637	690
Revenue: Primary Care: Prevnar fa...		2,236	2,305	2,571	2,920	2,638
Revenue: Primary Care: Prevnar fa...		4,204	4,032	2,701	2,930	3,209
Revenues: Specialty Care: Refacto...		171	180	240	295	333
Revenues: Specialty Care: Refacto...		59	59	64	74	92
Revenue: Specialty Care: Sulperaz...		757	786	683	618	684
Revenues: Specialty Care: Somaver...		158	157	179	169	159
Revenues: Specialty Care: Somaver...		109	111	98	108	105
Revenues: Oncology: Inlyta: Unite...		642	618	599	523	295
Revenues: Oncology: Inlyta: Total...		394	385	403	264	381
Revenues: Oncology: Xalkor: Unite...		100	105	102	138	149
Revenues: Oncology: Xalkori: Tota...		274	361	391	406	381
Revenues: Specialty Care: Xeljanz...		1,154	1,129	1,647	1,706	1,636
Revenues: Specialty Care: Xeljanz...		549	668	808	731	606
Revenue: Primary Care: Total Inte...		18,119	44,521	12,410	--	--
Revenue: Primary Care: United Sta...		12,470	28,503	3,815	--	--
Revenue: Primary Care: Nurtec ODT...		20	2	0	--	--
Revenue: Primary Care: Nurtec ODT...		908	211	0	--	--
Revenues: Pfizer CentreOne: Unite...		345	383	524	400	437
Revenues: Pfizer CentreOne: Total...		920	952	1,206	526	374
Revenue: Primary Care: Comirnaty ...		8,816	29,032	10,353	--	--
Revenue: Primary Care: Paxlovid: ...		-1,289	10,514	76	--	--
Revenue: Primary Care: Paxlovid: ...		2,568	8,419	0	--	--
Revenues: Primary Care: Eliquis a...		4,228	3,822	3,160	2,688	2,343

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Revenues: Oncology: Ibrance: Worl...		--	1,118	1,244	1,247	1,144
Revenues: FSME-IMMUN/TicoVac [$M]		--	30	91	101	45
Revenues: Pharmaceutical: Oncolog...		397	129	110	102	92
Revenues: Oncology: Xtandi allian...		418	314	313	305	258
Revenues: Oncology: Xtandi allian...		418	314	0	305	258
Revenues: Specialty Care: Inflect...		158	117	121	74	178
Revenues: Oncology: Bosulif: Worl...		145	182	160	154	150
Revenue - Oncology: Medrol [$M]		--	76	89	80	93
Pfizer Biopharma: Total [$M]		--	13,867	12,930	12,418	17,971
Revenues: Primary Care: Comirnaty...		--	5,361	1,307	1,488	3,064
Revenue: Primary Care: Nimenrix: ...		--	58	43	38	40
Revenue: Primary Care: Nurtec ODT...		--	282	233	247	167
Revenue: Specialty Care: Oxbryta:...		84	96	85	77	71
Revenues: Specialty Care: Zavicef...		--	133	130	132	116
Revenues: Pharmaceutical: Primary...		770	457	452	463	456
Revenues: Pharmaceutical: Oncolog...		--	88	88	100	114
Revenues: Pharmaceutical: Oncolog...		--	88	100	106	129
Revenues: Pharmaceutical: Oncolog...		116	57	56	50	49
Revenues: Pharmaceutical: Oncolog...		164	146	159	121	112
Revenues: Pharmaceutical: Oncolog...		--	46	45	43	40
Revenues: Pharmaceutical: Oncolog...		--	65	54	59	58
Revenues: Pharmaceutical: Oncolog...		--	79	82	87	93
Revenues: Pharmaceutical: Oncolog...		--	23	0	33	34
Revenues: Pharmaceutical: Special...		--	156	140	163	126
Revenues: Pharmaceutical: Special...		--	156	140	163	126
Revenues: Specialty Care: All oth...		--	272	270	269	374
Revenues: Specialty Care: All oth...		205	558	527	606	569
Revenues: Primary Care: Paxlovid ...		--	-3,135	202	143	4,069
Revenue: Specialty Care - Cibinqo...		--	37	37	38	--
Revenue: Business Innovation - Pf...		17	20	10	10	4
Revenues: Specialty Care: BeneFIX...		103	103	107	106	109
Revenue-Pharmaceutical: BMP2 [$M]		--	86	82	84	86
Revenues: Specialty Care: Genotro...		--	160	158	74	147
Revenues: Specialty Care: Fragmin...		--	63	57	59	58
Revenues: Specialty Care: Vfend: ...		--	34	46	56	51
Revenues: Specialty Care: Zithrom...		--	152	60	44	150
Revenue-Pharmaceutical: Oncology-...		--	76	76	72	77
Revenues: Oncology: Sutent: World...		--	44	42	45	50
Revenues: Specialty Care: Refacto...		--	52	61	56	60
Revenues: Specialty Care: Sulpera...		--	138	122	177	320
Revenues: Specialty Care: Somave...		--	67	69	65	66
Revenues: Oncology: Inlyta: World...		237	263	252	262	259
Revenues: Oncology: Xalkori: Worl...		--	91	86	86	111
Revenue: Primary Care: Worldwide ...		7,211	6,986	6,287	5,810	11,505
Revenue: Specialty Care: Worldwid...		3,843	3,949	3,757	3,653	3,612
Revenues: Oncology: Worldwide [$M...		3,549	2,932	2,885	2,956	2,855
Revenues: Pfizer CentreOne: World...		258	363	291	306	306
Revenues: Primary Care: Eliquis a...		626	1,612	1,498	1,762	1,874
Revenues: Primary Care: Prevnar f...		1,691	1,605	1,854	1,388	1,593
Revenues: Primary Care: Premarin ...		--	98	92	95	112
Revenues: Specialty Care: Vyndaqe...		1,137	961	892	782	686
Revenues: Specialty Care: Xeljanz...		194	493	503	469	237
Revenues: Specialty Care: Enbrel:...		159	203	208	219	199
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Revenues: Oncology: Ibrance; Unit...		--	712	838	850	750
Revenues: Oncology: Ibrance: Tota...		--	405	406	397	394
Revenues: FSME-IMMUN/TicoVac - US...		--	0	1	2	--
Revenue: Pharmaceutical-All Other...		183	93	78	69	60
Revenue: Pharmaceutical-All Other...		214	36	32	33	32
Revenue: FSME/IMMUN-TicoVac: ROW ...		--	30	90	100	45
Revenues: Specialty Care: Inflect...		96	63	61	15	119
Revenues: Specialty Care: Inflect...		62	54	61	59	59
Revenues: Primary Care: Eliquis a...		626	681	615	610	613
Revenues: Oncology: Bosulif: Unit...		101	120	114	106	105
Revenues: Oncology: Bosulif: Tota...		44	62	46	48	44
Revenue: Pharmaceutical-Oncology ...		2,572	1,932	1,881	1,973	1,841
Revenue: Pharmaceutical-Oncology ...		977	999	1,004	983	1,014
Pfizer Biopharma: US [$M]		--	4,490	7,717	6,095	8,396
Pfizer Biopharma: ROW [$M]		--	9,376	5,214	6,323	9,575
Revenues: Specialty Care: Vyndaqe...		751	534	511	434	384
Revenues: Specialty Care: Vyndaqe...		386	427	381	348	302
Revenue: Primary Care: Nimenrix: ...		--	58	0	38	40
Revenue: Specialty Care: Oxbryta:...		80	94	83	76	71
Revenue: Specialty Care: Oxbryta:...		4	2	2	1	0
Revenues: Specialty Care: Zavicef...		125	133	130	132	116
Revenues: Pharmaceutical: Primary...		315	73	78	98	109
Revenues: Pharmaceutical: Primary...		454	384	374	365	347
Revenue: Specialty Care - Cibinq...		23	20	8	10	--
Revenue: Specialty Care - Cibinq...		19	18	28	27	--
Revenue: Specialty Care - All oth...		--	62	57	64	118
Revenue: Specialty Care - All oth...		--	210	213	205	256
Revenue: Specialty Care - All oth...		83	298	287	357	346
Revenue: Specialty Care - All oth...		123	260	241	249	223
Revenue: Pharmaceutical-Specialty...		1,759	1,771	1,746	1,615	1,469
Revenue: Pharmaceutical-Specialty...		2,084	2,178	2,011	2,038	2,143
Revenue: Pharmaceutical- Oncology...		--	66	66	74	98
Revenue: Pharmaceutical- Oncology...		--	22	34	32	32
Revenue: Pharmaceutical- Oncology...		--	62	69	84	94
Revenue: Pharmaceutical- Oncology...		--	26	19	16	21
Revenue: Pharmaceutical- Oncology...		--	58	61	68	72
Revenue: Pharmaceutical- Oncology...		--	21	21	19	21
Revenue: Pharmaceutical-Oncology-...		59	60	60	53	52
Revenue: Pharmaceutical-Oncology-...		104	86	99	68	61
Revenue: Pharmaceutical-Oncology-...		--	36	28	35	35
Revenue: Pharmaceutical-Oncology-...		--	28	26	24	23
Revenue: Pharmaceutical-Oncology-...		111	55	53	48	47
Revenue: Pharmaceutical-Oncology-...		5	2	3	2	2
Revenue: Pharmaceutical-Oncology-...		--	-8	-22	12	10
Revenue: Pharmaceutical-Oncology-...		--	32	22	21	24
Revenue: Pharmaceutical-Oncology-...		--	46	43	42	39
Revenue: Pharmaceutical-Oncology-...	--	--	0	2	1	1
Geographic Revenue: United States...		9,514	4,591	7,804	6,185	8,507
Geographic Revenue: Total Interna...		5,365	9,657	5,427	6,548	9,775
Revenue: Primary Care: Comirnaty ...		2,172	1,064	1,645	1,967	2,060
Revenues: Specialty Care: BeneFIX...		47	49	52	48	50
Revenues: Specialty Care: BeneFIX...		56	54	54	58	59
Revenue-Pharmaceutical: BMP2-Unit...		--	86	82	84	86
Revenues: Specialty Care: Enbrel:...		159	203	208	219	199
Revenues: Specialty Care: Genotro...		90	112	104	90	80
Revenues: Specialty Care: Genotro...		30	47	54	-16	67
Revenue-Pharmaceutical: Fragmin-I...		--	63	56	59	58
Revenue-Pharmaceutical: Fragmin-U...		--	0	1	1	1
Revenue-Pharmaceutical: Infectiou...		--	1	2	1	1
Revenue-Pharmaceutical: Infectiou...		--	33	44	54	50
Revenue-Pharmaceutical: Infectiou...		199	152	59	44	149
Revenue-Pharmaceutical-Medrol: In...		--	55	50	50	51
Revenue-Pharmaceutical-Medrol: Un...		--	21	39	31	42
Revenue-Pharmaceutical: Oncology-...		--	75	75	71	76
Revenue-Pharmaceutical: Oncology-...		--	0	0	1	1
Revenues: Oncology: Sutent: Total...		--	39	38	40	42
Revenues: Oncology: Sutent: Unite...		--	4	3	5	8
Revenues: Primary Care: Premarin ...		--	10	9	9	9
Revenues: Primary Care: Premarin ...		--	88	83	86	104
Revenue: Primary Care: Prevnar fa...		--	612	544	563	518
Revenue: Primary Care: Prevnar fa...		1,149	994	1,310	825	1,075
Revenues: Specialty Care: Refacto...		--	38	46	43	44
Revenues: Specialty Care: Refacto...		--	14	15	14	16
Revenue: Specialty Care: Sulperaz...		167	138	122	177	320
Revenues: Specialty Care: Somaver...		--	40	41	40	38
Revenues: Specialty Care: Somaver...		--	27	28	25	28
Revenues: Oncology: Inlyta: Unite...		141	166	153	168	155
Revenues: Oncology: Inlyta: Total...		96	97	98	94	104
Revenues: Oncology: Xalkor: Unite...		--	25	22	25	27
Revenues: Oncology: Xalkori: Tota...		--	66	64	61	83
Revenues: Specialty Care: Xeljanz...		74	360	371	333	90
Revenues: Specialty Care: Xeljanz...		120	133	132	136	147
Revenue: Primary Care: Total Inte...		2,117	6,200	2,198	3,303	6,418
Revenue: Primary Care: United Sta...		5,095	787	4,089	2,507	5,087
Revenue: Primary Care: Nurtec ODT...		--	7	6	4	4
Revenue: Primary Care: Nurtec ODT...		--	275	227	244	163
Revenues: Pfizer CentreOne: Unite...		71	82	78	81	106
Revenues: Pfizer CentreOne: Total...		187	281	214	225	200
Revenue: Primary Care: Comirnaty ...		--	4,297	312	1,471	2,735
Revenue: Primary Care: Paxlovid: ...		1,800	-3,249	0	0	1,960
Revenue: Primary Care: Paxlovid: ...		234	114	202	143	2,109
Revenues: Primary Care: Eliquis a...		1,413	931	883	1,152	1,261

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators